CoChat
Sign Up
Cited by 726Renal Diseases and GlomerulopathiesChronic Kidney Disease and DiabetesVasculitis and related conditions

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Intensive Supportive Care plus Immunosuppression in IgA Nephropathy

Open access
Rauen, Thomas, Eitner, Frank, Fitzner, Christina, Sommerer, Claudia, Zeier, Martin, Otte, Britta, Panzer, Ulf, Peters, Harm, Benck, Urs, Mertens, Peter R., Kuhlmann, Uwe, Witzke, Oliver, Gross, Oliver, Vielhauer, Volker, Mann, Johannes F.E., Hilgers, Ralf-Dieter, Floege, Jürgen·2015·New England Journal of Medicine
DOI 10.1056/nejmoa1415463
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: The outcomes of immunosuppressive therapy, when added to supportive care, in patients with IgA nephropathy are uncertain. METHODS: We conducted a multicenter, open-label, randomized, controlled trial with a two-group, parallel, group-sequential design. During a 6-month run-in phase, supportive care (in particular, blockade of the renin-angiotensin system) was adjusted on the basis of proteinuria. Patients who had persistent proteinuria with urinary protein excretion of at least 0.75 g per day were randomly assigned to receive supportive care alone (supportive-care group) or supportive care plus immunosuppressive therapy (immunosuppression group) for 3 years. The primary end points in hierarchical order were full clinical remission at the end of the trial (protein-to-creatinine ratio <0.2 [with both protein and creatinine measured in grams] and a decrease in the estimated glomerular filtration rate [eGFR] of <5 ml per minute per 1.73 m(2) of body-surface area from baseline) and a decrease in the eGFR of at least 15 ml per minute per 1.73 m(2) at the end of the trial. The primary end points were analyzed with the use of logistic-regression models. RESULTS: The run-in phase was completed by 309 of 337 patients. The proteinuria level decreased to less than 0.75 g of urinary protein excretion per day in 94 patients. Of the remaining 162 patients who consented to undergo randomization, 80 were assigned to the supportive-care group, and 82 to the immunosuppression group. After 3 years, 4 patients (5%) in the supportive-care group, as compared with 14 (17%) in the immunosuppression group, had a full clinical remission (P=0.01). A total of 22 patients (28%) in the supportive-care group and 21 (26%) in the immunosuppression group had a decrease in the eGFR of at least 15 ml per minute per 1.73 m(2) (P=0.75). There was no significant difference in the annual decline in eGFR between the two groups. More patients in the immunosuppression group than in the supportive-care group had severe infections, impaired glucose tolerance, and weight gain of more than 5 kg in the first year of treatment. One patient in the immunosuppression group died of sepsis. CONCLUSIONS: The addition of immunosuppressive therapy to intensive supportive care in patients with high-risk IgA nephropathy did not significantly improve the outcome, and during the 3-year study phase, more adverse effects were observed among the patients who received immunosuppressive therapy, with no change in the rate of decrease in the eGFR. (Funded by the German Federal Ministry of Education and Research; STOP-IgAN ClinicalTrials.gov number, NCT00554502.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1415463

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 33 references

Research works printed but not linked: 3

  1. Eitner F, 2008, J Nephrol, 21, 284
  2. International Conference on Harmonisation E9 Expert Working Group, 1999, Stat Med, 18, 1905
  3. Kanno Y, 2000, Clin Nephrol, 54, 360

Cited by

Sorted by citations

Items 201–300 of 726

Related

See all

Metadata

Authors
Rauen, T., Eitner, F., Fitzner, C., Sommerer, C., Zeier, M., Otte, B., Panzer, U., Peters, H., Benck, U., Mertens, P. R., Kuhlmann, U., Witzke, O., Gross, O., Vielhauer, V., Mann, J. F. E., Hilgers, R.-D., & Floege, J.
Affiliations
  • Heidelberg University (DE)
  • RWTH Aachen University (DE)
  • University Hospital Münster (DE)
  • University Medical Center Hamburg-Eppendorf (DE)
  • Charité – Universitätsmedizin Berlin (DE)
  • Otto-von-Guericke-Universität Magdeburg (DE)
  • Essen University Hospital (DE)
  • Universitätsmedizin Göttingen (DE)
  • LMU Klinikum (DE)
  • München Klinik (DE)
ORCID
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2015-12-03
Volume
373
Issue
23
Pages
2225-2236
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa1415463
OpenAlex
W2186629139
Cited by
726
References
33
Citations by year
2026: 52 · 2025: 72 · 2024: 85 · 2023: 85 · 2022: 69 · 2021: 82 · 2020: 77 · 2019: 48 · 2018: 49 · 2017: 50 · 2016: 50 · 2015: 5
FWCI
44.38
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
  • GRO (submittedVersion, cc-by)
  • RWTH Publications (RWTH Aachen) (submittedVersion)
Topics
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
Keywords
IgA nephropathy, immunosuppressive therapy, supportive care, renin-angiotensin system blockade, proteinuria, clinical remission, estimated glomerular filtration rate decline, renal function decline, impaired glucose tolerance, weight gain, kidney disease progression, urine protein-to-creatinine ratio, run-in phase
MeSH terms
Adult, Angiotensin-Converting Enzyme Inhibitors, Combined Modality Therapy, Critical Care, Female, Glomerular Filtration Rate, Glomerulonephritis, IGA, Glucocorticoids, Humans, Immunosuppression Therapy, Male, Middle Aged, Proteinuria, Renin-Angiotensin System, Logistic Models, Treatment Failure, Angiotensin II Type 2 Receptor Blockers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review